Mallinckrodt receives court approval for "first day" motions to support ongoing operations

Continuing to serve customers and deliver high-quality therapies to patients without interruption; vendors and suppliers to be paid in full in the ordinary course dublin , aug. 30, 2023 /prnewswire/ -- mallinckrodt plc (otcmkts: mnktq) ("mallinckrodt" or the "company"), a global specialty pharmaceutical company, today announced that it has received approvals from the u.s. bankruptcy court for the district of delaware for its "first day" motions related to the company's voluntary chapter 11 petitions filed on august 28, 2023. as expected, the court granted mallinckrodt approval to access $150 million of the $250 million of commitments for new financing it received from certain of its creditors, as well as new borrowing availability from lenders under its asset-based loans.
MNK Ratings Summary
MNK Quant Ranking